Kornimate/medical-research-clean huggingface dataset:
predictors and clinical outcomes of patients with coronary heart disease co-morbid depression post percutaneous coronary intervention

Conditions: Coronary Heart Disease; Percutaneous Coronary Intervention; Depression

Summary: a prospective, multicenter, registered cohort study to observe the incidence of 1-year major adverse cardiac events in patients with coronary heart disease co-morbid depression treated with percutaneous coronary intervention and to clarify the predictors of 1-year major adverse cardiac events post pci among these patients.

coronary heart disease (chd) is a clinical relevant psychosomatic issue. treatment strategies include percutaneous coronary intervention (pci), guidelines medication (gdmt) and coronary artery bypass grafting (cabg) were clinical proven to be effective to realize myocardial revascularization post chd. previous studies revealed that diagnosed depressed chd patients have 3.6 times higher risk of major adverse events (mace) post percutaneous coronary intervention than nondepressed. however, a reliable explanation of how depression impact clinical outcomes of chd patients post pci is lacking. the objective of this study is to observe the incidence of major adverse cardiovascular events in patients with coronary heart disease co-morbid with depression post pci, and to explore a prognostic model of clinical outcomes based on physiological, interventional, socio-economic and psychological factors among these patients.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures; 2. men and women 18 years or older； 3. diagnosed chd needed to and can be treated with pci according to the guidelines of acc/aha； 4. willingness to participate in the follow-up study for at least 1 year. exclusion criteria: 1. inability to provide written informed consent; 2. diagnosed mental illness or medical history (including schizophrenia, bipolar disorder, severe dementia or lifetime alcohol or substance abuse); 3. tendency of suicide; 4. pregnant or lactating women; 5. any physical or intellectual inability or disability that may affect completion of self-assessment tools, study protocol and follow-up requirements; 6. any other reasons that investigators based on professional judgments that would place the patient at increased risk. 7. patient with stemi within 24-hour from the onset of chest pain to admission.
safety and efficacy of fluocinolone acetonide intravitreal implants

Conditions: Noninfectious Posterior Uveitis

Summary: this is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide (fa) intravitreal implants for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye. an additional objective is to compare the safety and efficacy of two doses of fluocinolone acetonide.


Eligibility criteria:
inclusion criteria: * males or non-pregnant females at least 6 years of age who had been diagnosed and treated for recurrent, non-infectious uveitis affecting the posterior segment of one or both eyes for at least 1 year prior to the start of the study, and had 'quiet' eyes at surgery exclusion criteria: * coexisting medical or ocular conditions that would interfere with the study results
the vppg-detecting software guided management of cirrhotic portal hypertension

Conditions: Portal Hypertension; Cirrhosis, Liver

Summary: the aim of this study is to investigate the possibilities and effectiveness of managing cirrhotic portal hypertension using the non-invasive portal pressure gradient (ppg) detecting software. in this study, the three-dimensional reconstruction and natural follow-up methods have been respectively applied in the experimental (1st) and active comparator (2nd) group. the virtual ppg is calculated with anatomical and hemodynamic information of portal system collected by ultrasound and ct tests. cirrhosis patients in the 1st group, with calculated vppg values, are managed with upper gi endoscopic results. besides, patients in the 2nd group, are managed according to the most updated chinese clinical guideline for cirrhotic portal hypertension, namely, patients with either liver stiffness measurement (lsm) \>15kpa or plt count \<150\*10\^9 should be screened and treated with upper gi endoscopy. the morbidity of decompensated cirrhotic events and mortality of patients in two arms will be compared. the cutoff values of vppg to spare endoscopies with low missed vnt (varices needing treatment) are preliminarily determined with the cohort data.


Eligibility criteria:
inclusion criteria: inpatients (shanghai tongji hospital) with cirrhosis, which is confirmed by the imaging tests (upper abdominal ultrasound/ct/mri) or liver biopsy pathology. exclusion criteria: * 1. portal vein embolism; * 2. splenectomy; * 3. hepatic encephalopathy; * 4. hepatic space occupying lesions (such as hepatic cysts, hemangiomas, etc.) with diameter \> 3cm and local compression effect; * 5. contraindications of enhanced ct test, such as iodine allergy, peripheral veins are too thin to inject contrast medium; * 6. contraindications of upper gi endoscopy

Keywords: virtual portal pressure gradient enhanced upper abdominal ct portal ultrasound portal hypertension cirrhosis
immune function status and the prevalence of hepatitis in postpartum pregnant women with chb infection

Conditions: Chronic Hepatitis B

Summary: to date, several studies have manifested that high levels of adrenal corticosteroids and oestrogen hormones during pregnancy can lead to increased hbv viraemia. these hormonal and immune function status changes can result in minimal fluctuations in liver function tests. serum alanine aminotransferase (alt) tends to increase in late pregnancy and the postpartum period. peripartum hepatitis flares leading to hepatic decompensation have been reported.therefore, the investigators aim to detect and observe the immune function status and incidence of hepatitis in pregnant women with chronic hepatitis b virus infection in late pregnancy and the postpartum period.to provide a clinical evidence for the administration of chronic hepatitis b virus infection pregnant women.

in this trial, pregnants who were positivity for serum hbsag for more than 6 months and hbeag , hbv dna \>106iu/ml, alanine aminotransferase (alt) below 35 iu/ml (uln=40iu/ml) and no received nucleoside analogue antiviral therapy were enrolled into group a, in addition ,the chb infection pregnants with undetectable hbvdna were enrolled into group b(control group).in which, all pregnants were chronic hbv infection without compensated cirrhosis,hepatic adipose infiltration,icp, hypertension ,heart disease, postpartum hemorrhage. none of the mothers were co-infected with hepatitis a,c,d,e,or hiv;syphilis, epstein-barr virus.serum hbv dna load(roche, pleasanton, ca, usa), hbsag/anti-hbs level, hbeag/anti-hbe routine blood test, liver function, renal function will be tested piror to delivery and postpartum 2,6,12 weeks. plasmacytoid dendritic cells(pdcs) and natural killer(nk)cells,cd4＋t cells and regulatory t (treg) cells were detected by flow cytometry. plasma cytokines interferon-alpha 2(ifn-α2) / interferon-gamma (ifn-γ) / transforming growth factor beta1 (tgf-β1) / interleukin-2 (il-2) / interleukin-6 (il-6)/interleukin-10(il-10) / interleukin-17a (il-17a) / tumor necrosis factor-α1(tnf-α1)were measured by luminex at the above time point except 2 weeks.

Eligibility criteria:
inclusion criteria: * pregnants who were positivity for serum hbsag for more than 6 months and hbeag , hbv dna \>106iu/ml/undetectable hbvdna ,alanine aminotransferase (alt) below 35 iu/ml (uln=40iu/ml) and no received nucleoside analogue antiviral therapy exclusion criteria: * compensated cirrhosis,hepatic adipose infiltration,icp. hypertension ,heart disease. postpartum hemorrhage. pregnants who were co-infected with hepatitis a,c,d,e,or hiv;syphilis,epstein-barr virus.

Keywords: chronic hepatitis b pregnancy cellular immune response clinical implications
diabetes communication and treatment burden

Conditions: Diabetes Mellitus, Type 2; Multiple Chronic Conditions

Summary: the objective of this proposal is to pilot test two types of pre-visit planning, where clinical staff reviews charts and talks to patients before their doctors appointments, to reduce the burden of diabetes care on the patient without increasing the visit workload during busy primary care clinics.


Eligibility criteria:
inclusion criteria: patients: * patient at the ucd acc family medicine residency clinic * age 18+, * has diabetes per diabetes registry (healthyplanet2020) * plus at least one other chronic condition * attends a primary care office visit (in-person or telehealth) during the study initial data collection period with a physician who is participating in the study * speaks and writes english well enough to complete a written or oral survey * consents to participate pcps: -sees patients as a primary care physician at the study clinic site exclusion criteria: * does not meet inclusion criteria
neural integrity monitor electromyogram (nim-emg) endotracheal tube intubation with video laryngoscope

Conditions: Intubation; Difficult or Failed; Airway Complication of Anesthesia; Pain, Postoperative; Anesthesia Intubation Complication

Summary: laryngeal nerve monitoring is performed to prevent intraoperative nerve damage in thyroidectomy operations. nim-emg intubation tube is used while monitoring the recurrent laryngeal nerve. care should be taken when placing this tube. ensure that the electrodes on the tube are in contact with the vocal cords. both the macintosh laryngoscope and the videolaryngoscope can be used when inserting the nim-emg tube. the aim of our study is to compare these two intubation methods.

anesthesiologists play a key role for the medications used for anesthesia and placement of the endotracheal tube in operations with intraoperative monitoring. while placing the nim-emg tube, the size of the endotracheal tube is very important so that the tube can contact the vocal cords. the placement of the tube may change due to reasons such as movement of the neck during the operation. in addition, endotracheal tube placement may be problematic due to poor vision during direct laryngoscopy. incorrect placement of the tube may result in equipment inoperability and increase the likelihood of injury to the recurrent laryngeal nerve. laryngoscopy is a term for tracheal intubation that provides visualization and evaluation of the larynx with its upper airway structures. until recently, direct laryngoscopy was considered the standard technique for endotracheal intubation. recently, a wide variety of methods have been developed for endotracheal intubation. video laryngoscopes are similar to direct laryngoscopes but provide laryngeal imaging with a small video chip on their blade. this imaging is superior compared to direct laryngoscopy. the aim of the study was to compare the use of direct laryngoscopy and video laryngoscopy in intubation with the nim-emg tube, which is routinely used in operations where the recurrent laryngeal nerve (rln) may be damaged, in terms of intubation success, intubation time, tracheal intubation comfort, hemodynamic responses, surgical satisfaction, and complications that may develop after anesthesia or surgery.

Eligibility criteria:
inclusion criteria: * the american society of anesthesiologists (asa) physical status classification system 1-2 * age 18-65 * undergoing elective thyroid and parathyroidectomy surgery * undergoing intraoperative recurrent laryngeal nerve monitoring exclusion criteria: * history of head and neck surgery * body mass index less than 19 or greater than 30 * muscle relaxant allergy * lidocaine allergy * ids score \>5 * uncontrolled hypertension, bronchial asthma, tracheal pathology * undergoing emergency surgery * cases that cannot give informed consent

Keywords: videolaryngoscopy nim-emg intubation tube thyroidectomy airway management
study to identify and characterize bacteria causing acute otitis media in south african children

Conditions: Acute Otitis Media

Summary: the purpose of this study is to identify and characterize the bacteria causing acute otitis media episode in hiv-positive and hiv-negative children (\>=3 months to \<5 years) in south africa. middle ear fluid sampling either by tympanocentesis or by careful sampling of spontaneous otorrhoea will be done; nasopharyngeal aspirate and urine sample will also be collected from the subjects.


Eligibility criteria:
inclusion criteria: inclusion criteria for all subjects: * age: \>= 3 months and \< 5 years at the time of enrolment. * signs, symptoms, and conditions: * one of the functional or general signs of otalgia,, conjunctivitis, fever and either * paradise's criteria or * spontaneous otorrhoea of less than 24 hours. * subject will be included as a treatment failure case. * written informed consent obtained from parent or guardian prior to study start. inclusion criteria for hiv-positive subjects: * documented hiv-positive status as given in subject's medical records. or * subjects referred from paediatric hiv clinic. inclusion criteria for hiv-negative subjects (including presumed negative children) * children who have been tested hiv-negative. * children whose mothers volunteer to have tested hiv-negative whilst pregnant with the index case and the child is free to any world health organization grade ii stigmata of hiv/acquired immunodeficiency syndrome. * children who do not fulfil the world health organization staging for hiv infection / immunosuppression. exclusion criteria: * hospitalised during the diagnosis of acute otitis media or during treatment. * otitis externa or otitis media with effusion. * presence of a transtympanic aerator. * systemic antibiotic treatment received for a disease other than acute otitis media in the 72 hours prior to enrolment. * receiving antimicrobial prophylaxis for recurrent acute otitis media but excluding cotrimoxazole or isoniazid prophylaxis in hiv exposed children. * provision of antibiotic by paediatrician/ent specialist at the enrolment visit prior to the sampling of the middle ear fluid or spontaneous otorrhoea. * children on antibiotics for acute otitis media who are clinically improving.
endoscopic ultrasound guided coeliac plexus neurolysis for cancer pain

Conditions: Malignancy; Pain Management

Summary: many cancer patients suffer from intractable pain and which is often suboptimally controlled by even strong opioid analgesics. coeliac plexus neurolysis (cpn) is procedure which intended to permanently destroy the nociceptive pathway that transmits the pain caused by the tumour. it can be with different approaches, such as percutaneously guided by fluoroscopy, echo-endoscopically or surgically with endoscopic approach being the more popular one in many centers equipped with echo-endoscopic services. the effect of cpn has been well established by some retrospective series. the overall response rate to cpn ranges from 70-90%, however, the analgesic effect is limited and up to roughly around 3 months. it is believed that the short-lasting analgesic effect is related to incomplete neurolysis by absolute alcohol injection. recently, radiofrequency ablation (rfa) of coeliac plexus has been introduced as another mode of cpn. so far, only one small single center randomized controlled trial (rct) suggesting superior performance in favour to cpn using rfa. this result has to be validated and by a rct with larger sample size. in addition, data concerning the quality of life (qol) improvement and cost-effectiveness need to be further elucidated. therefore, the aim of this study is to perform a rct to look into these issues.

the aim of this study is to compare the efficacy of eus-cpn by chemical ablation using alcohol injection versus by radiofrequency ablation in patients with cancer pain related to intra-abdominal malignancy. this is a randomised controlled trial to assess the clinical outcomes and cost-effectiveness of this new treatment approach.

Eligibility criteria:
inclusion criteria: * age ≥18 year-old * patients who give informed consent to the study * suboptimal pain control with regular analgesics * inoperable cancer of pancreas, biliary system and liver (both primary or secondary) exclusion criteria: * patients who refuse to give consent * patients aged \<18 years * eus not possible due to: * problem related to scope insertion such as trismus, stenosis of the upper gi tract * coagulopathy with inr \>1.5 or platelet count \< 70 * low oxygen saturation or extreme blood pressure render endoscopic procedure unsafe

Keywords: endoscopic ultrasound guided radiofrequency ablation coeliac plexus neurolysis intra-abdominal malignancy pain relief chemical coeliac plexus neurolysis coeliac plexus ablation cancer pain
assesment of hearing in patients with vestibular migra

Conditions: Vestibular Migraine

Summary: evaluation of hearing in patients with vestibular migraine


Eligibility criteria:
inclusion criteria: * vertigo exclusion criteria: * hypertension
a study of mhb039a for advanced solid tumor

Conditions: Advanced Solid Tumor

Summary: phase i/ii open label, multicenter study to evaluate the efficacy and safety of mhb039a in advanced malignant tumors.

this first-in-human, dose escalation and dose expansion study is to evaluate the safety, tolerability, pharmacokinetics (pk), immunogenicity, pharmacodynamics (pd) and anti-tumor activity of mhb039a in patients with advanced solid tumor. the phase i stage （dose escalation）is to determine the maximum tolerated dose (mtd). the phase ii stage （dose expansion）is to determine the recommended phase 2 dose (rp2d) according to safety and efficacy in specific tumor types.

Eligibility criteria:
inclusion criteria: * histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy. * written and signed informed consent * aged 18 years or older * eastern cooperative oncology group (ecog) performance score of 0 or 1 * life expectancy \>=3 months exclusion criteria: * prior malignancy active within the previous 5 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or others) * receiving any chemotherapy within 3 weeks prior to the first dose；or other systemic anticancer therapy within 4 weeks prior to the first dose * receiving prior anti-pd-1, anti-pd-l1, anti-ctla(cytotoxic t-lymphocyte-associated protein)-4 or any other immunotherapy or immune-oncology (io) agent within 28 days of first dose with mhb039a or experienced a toxicity that led to permanent discontinuation of prior immunotherapy * unresolved toxicities from prior anticancer therapy
observational usage study of statins in primary care in france

Conditions: Healthy

Summary: to describe the way statins are used in france in primary care, that is to determine patients profile (particularly cv risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin


Eligibility criteria:
inclusion criteria: * patients to whom a statin was initiated or switched between 3 and 6 months before consultation

Keywords: statins rosuvastatin cross sectional study france cv risk factors
treating the resistant patent ductus arteriosus (pda)

Conditions: Patent Ductus Arteriosus

Summary: persistent postnatal ductal patency may have significant adverse hemodynamic effects, frequently necessitating therapeutic intervention in order to facilitate ductal closure. medical therapy for patency of the ductus arteriosus is successful mediating ductal closure in approximately 70% of treated infants. in a recent study in our population, 17% of the babies showed no ductal response to the first course of treatment and 9.4% of our study infants eventually underwent surgical ligation of the ductus after failure of medical therapeutic closure.we propose to evaluate and compare two alternate therapeutic approaches to ductal closure in babies who do not respond to initial therapy.


Eligibility criteria:
inclusion criteria: * inborn premature neonates admitted to the neonatal intensive care unit of the shaare zedek medical center and diagnosed as having a hemodynamically significant patent ductus arteriosus (spda) will be considered as potential candidates for study if/when they do not respond to initial therapy exclusion criteria: * any baby not considered viable * any baby with ivh grade 3-4 of recent onset (within 3 days. \[if no head ultrasound has been performed within the last 3-4 days, one should performed prior to onset of study.\] * any baby with dysmorphic features or congenital abnormalities * any baby with structural heart disease other than pda * any baby with documented infection, * any baby with thrombocytopenia (\<50,000).

Keywords: pda indomethacin pentoxifylline patent ductus arteriosus [pda] resistant to therapy
the effects of anti-infective central venous catheter on catheter-related infection in critically patients

Conditions: Critical Illness

Summary: the purpose of this study is to investigate the effect of anti-infective central venous catheter(certofix®protect) on reducing catheter-related bloodstream infection in critically ill patients in china, and the relationship between catheter-related bloodstream infection and catheter-related thrombosis.


Eligibility criteria:
inclusion criteria: * adult patients in intensive care unit (icu)（age ≥ 18 years） * needs double lumen cvc more than 5 days * signed informed consent exclusion criteria: * thrombosis in target and/or contralateral vein * pregnancy or lactating women * unlikely to survive for more than 1 month * bad prognosis * suspected catheter-related infection * replacement cvc in original site through guide wire * severe burn * situation that is not suitable for cvc, including allergic to cvc material, thrombosis in target vein, infection of puncture site, coagulation disorder, abnormal anatomy * already in this study * participated in other studies within 3 months

Keywords: central venous catheter (cvc) catheter-related bloodstream infection (crbsi) catheter-related thrombosis (crt)
a rollover study for patients who received tremelimumab in other protocols, to allow the patients access to tremelimumab until this agent becomes commercially available or development is discontinued.

Conditions: Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms; Patients Who Have/Have Had Melanoma and Other Tumors

Summary: this study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.


Eligibility criteria:
inclusion criteria: * the subject must have already received tremelimumab in another protocol * females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. the definition of effective contraception will be based on the judgement of the investigator. * subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures exclusion criteria: * none

Keywords: melanoma and other tumors